Pharma Focus Asia

SciSparc Launches Clinical Trial for Autism Spectrum Disorder Treatment, Commencing Dosing Phase

Friday, March 01, 2024

SciSparc Ltd. (Nasdaq: SPRC), a specialized clinical-stage pharmaceutical firm focusing on therapies for central nervous system disorders and rare diseases, has reported the successful manufacturing and delivery of its innovative SCI-210 treatment. This accomplishment coincides with the launch of enrollment for a clinical trial at the Soroka Medical Center, which targets pediatric patients with Autism Spectrum Disorder (ASD).

SCI-210, a proprietary treatment of SciSparc, combines cannabidiol-rich oil (CBD) and CannAmide™, the company's palmitoylethanolamide-based tablets.

SciSparc's CEO, Oz Adler, expressed excitement about reaching this milestone, stressing the potential of their treatment to enhance patients' lives through safer and more effective therapy. Adler emphasized the unique technology employed by SciSparc, which allows for lower doses of the active agent while maintaining efficacy and enhancing safety.

The clinical trial aims to meticulously assess the safety, tolerability, and efficacy of SCI-210 compared to CBD monotherapy for treating ASD. This randomized, double-blind, placebo-controlled trial with cross-over features a 20-week duration and aims to enroll 60 children. Primary efficacy endpoints include assessments such as the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire, the Clinical Global Impressions-Improvement (CGI-I) scale administered by healthcare professionals, and the determination of an effective therapeutic dosage.

The anticipated results of this trial may pave the way for SciSparc to proceed with the commercialization of SCI-210 in Israel.

 

Source: globenewswire.com

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference